Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Headlines,Novo Nordisk experienced a decline in stock value after recent news from its lab.,Eli Lilly, (NYSE:LLY),and Viking ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a ...

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...